查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1889578

2025年小干擾核糖核酸（RNA）全球市場報告

Small Interfering Ribonucleic Acid (RNA) Global Market Report 2025
出版日期: | 出版商: The Business Research Company | 英文 250 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

近年來，小干擾核糖核酸（siRNA）市場呈現指數級成長，預計將從2024年的156.5億美元成長到2025年的188.6億美元，複合年成長率達20.5%。過去幾年的成長可歸因於政府投入的增加、人們對遺傳疾病認知的提高、小干擾核糖核酸（siRNA）療法臨床試驗的擴大、生物技術基礎設施的擴展以及標靶治療的日益普及。

預計未來幾年，小干擾RNA（siRNA）市場將呈指數級成長，到2029年市場規模將達到392.6億美元，複合年成長率（CAGR）為20.1%。預測期內的成長可歸因於個性化醫療需求的不斷成長、siRNA研究投資的增加、製藥公司間合作的加強以及基於siRNA的藥物核准數量的增加。預測期內的關鍵趨勢包括遞送方法的技術進步、RNAi療法的創新、脂質奈米顆粒載體的開發、基因靜默的研究與開發以及標靶藥物遞送系統的進步。

預計未來幾年，對個人化醫療日益成長的需求將推動siRNA市場的成長。個人化醫療是一種根據患者的遺傳、環境和生活方式因素量身定做治療方法的方法，旨在最佳化治療效果並改善患者護理。基因組學技術的進步使得精準識別基因突變和個人化治療成為可能，從而提升了市場需求。小干擾RNA（siRNA）透過標靶基因靜默為個人化醫療提供支持，使其適用於治療特定的遺傳性疾病。 siRNA透過選擇性抑制致病mRNA，最大限度地減少脫靶效應，從而提高治療效果和患者預後。例如，根據美國非營利組織「個人化醫療聯盟」（Personalized Medicine Alliance）統計，截至2024年2月，美國食品藥物管理局（FDA）在2023年核准了26種新的個人化藥物，較2022年的12種顯著成長。因此，對個人化醫療日益成長的需求正在推動小干擾RNA（siRNA）市場的成長。

小干擾RNA（siRNA）療法市場的主要企業正在尋求監管部門核准其治療罕見遺傳疾病的新機制，旨在提供持久療效並減少給藥頻率。監管部門核准是指正式授權，允許治療方法安全地進行測試、上市或用於患者。例如，2025年3月，美國生物製藥公司Alnylam Pharmaceuticals, Inc.的Qfitlia（fitusiran）獲得了美國食品藥物管理局（FDA）的核准。 Qfitlia是第一個以siRNA為基礎的治療方法，適用於12歲以上患有A型或B型血友病（伴或不伴阻礙要素）的成人和青少年患者。該療法旨在降低抗凝血酵素水平並促進凝血酶生成，從而促進血液凝固並減少出血事件。 Qfitlia採用每兩個月一次的皮下注射給藥方案，為血友病治療提供了一種新型的非因子治療選擇。

目錄

第1章執行摘要

第2章 市場特徵

第3章 市場趨勢與策略

第4章 市場：宏觀經濟情景，包括利率、通貨膨脹、地緣政治、貿易戰和關稅，以及新冠疫情及其復甦對市場的影響

第5章 全球成長分析與策略分析框架

  • 全球小干擾核糖核酸（RNA）：PESTEL 分析（政治、社會、技術、環境、法律因素、促進因素和限制因素）
  • 終端用戶產業分析
  • 全球小干擾核糖核酸（RNA）市場：成長率分析
  • 全球小干擾核糖核酸（RNA）市場表現：規模與成長，2019-2024年
  • 全球小干擾核糖核酸（RNA）市場預測：規模與成長，2024-2029年，2034年預測
  • 全球小干擾核糖核酸（RNA）：潛在市場規模（TAM）

第6章 市場細分

  • 全球小干擾核糖核酸 (RNA) 市場按類型、表現和預測分類，2019-2024 年、2024-2029 年預測、2034 年預測
  • 脂質體全身療法
  • 基於奈米顆粒的全身性治療
  • 全球小干擾核糖核酸 (RNA) 市場：按適應症、表現和預測分類，2019-2024 年、2024-2029 年預測、2034 年預測
  • 心血管疾病
  • 呼吸系統疾病
  • 腫瘤學
  • 神經退化性疾病
  • 感染疾病
  • 全球小干擾核糖核酸 (RNA) 市場按最終用戶、性能和預測分類，2019-2024 年、2024-2029 年預測、2034 年預測
  • 醫院
  • 研究所
  • 製藥和生物技術公司
  • 學術機構
  • 全球小干擾核糖核酸 (RNA) 市場：按脂質體系統療法、類型、性能和預測進行細分，2019-2024 年、2024-2029 年預測、2034 年預測
  • 陽離子脂質體遞送
  • 中性脂質體遞送
  • 聚乙二醇化脂質體遞送
  • 標靶化脂質體遞送
  • 全球小干擾核糖核酸 (RNA) 市場：按奈米顆粒系統療法、類型、性能和預測進行細分，2019-2024 年、2024-2029 年預測、2034 年預測
  • 脂質奈米顆粒遞送
  • 聚合物奈米顆粒遞送
  • 金奈米顆粒遞送
  • 二氧化矽奈米顆粒遞送

第7章 區域和國家分析

  • 全球小干擾核糖核酸（RNA）市場：區域分析、預測與成長，2019-2024年、2024-2029年預測、2034年預測
  • 全球小干擾核糖核酸 (RNA) 市場：按國家、表現和預測分類，2019-2024 年、2024-2029 年預測、2034 年預測

第8章 亞太市場

第9章：中國市場

第10章 印度市場

第11章 日本市場

第12章：澳洲市場

第13章 印尼市場

第14章 韓國市場

第15章 西歐市場

第16章英國市場

第17章：德國市場

第18章：法國市場

第19章：義大利市場

第20章：西班牙市場

第21章 東歐市場

第22章 俄羅斯市場

第23章 北美市場

第24章美國市場

第25章：加拿大市場

第26章 南美洲市場

第27章：巴西市場

第28章 中東市場

第29章：非洲市場

第30章：競爭格局與公司概況

  • 小干擾核糖核酸（RNA）市場：競爭模式
  • 小干擾核糖核酸（RNA）市場：公司概況
    • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
    • Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
    • GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
    • Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
    • Sarepta Therapeutics Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章：其他領先和創新企業

  • Alnylam Pharmaceuticals Inc.
  • Ionis Pharmaceuticals Inc.
  • Wave Life Sciences Ltd.
  • Silence Therapeutics plc
  • Arrowhead Pharmaceuticals Inc.
  • Quark Pharmaceuticals Inc.
  • Arbutus Biopharma Corporation
  • Evox Therapeutics Ltd.
  • Phio Pharmaceuticals Inc.
  • Genecon Biotechnologies Co., Ltd.
  • Olix Pharmaceuticals, Inc.
  • Benitec Biopharma Ltd.
  • Bio-Path Holdings, Inc.
  • Calando Pharmaceuticals, Inc.
  • Sirnaomics, Ltd.

第32章 全球市場競爭基準化分析與儀錶板

第33章 重大併購

第34章 近期市場趨勢

第35章：高潛力市場國家、細分市場與策略

  • 2029年小干擾核糖核酸（RNA）市場：提供新機會的國家
  • 小干擾核糖核酸（RNA）市場展望 2029：新興細分市場機會
  • 小干擾核糖核酸 (RNA) 市場 2029 年：成長策略
    • 基於市場趨勢的策略
    • 競爭對手策略

第36章附錄

簡介目錄
Product Code: r40126

Small interfering ribonucleic acid (RNA) is a short, double stranded RNA molecule that plays a key role in gene silencing through a process called RNA interference (RNAi). It binds to complementary messenger RNA (mRNA) sequences, causing their degradation and preventing protein synthesis. The primary purpose of siRNA is to regulate or suppress the expression of specific genes, and it is often used in research and therapeutic applications to target disease causing genes.

The main types of small interfering ribonucleic acid (RNA) include liposome systemic therapy and nanoparticle based systemic therapy. Liposome systemic therapy is a drug delivery method that uses liposomes to carry therapeutic agents throughout the body via the bloodstream. These therapies are indicated for conditions such as cardiovascular diseases, respiratory diseases, oncology, neurodegenerative diseases, and infectious diseases, serving end users such as hospitals, research institutions, pharmaceutical and biotechnology companies, and academic institutions.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

The small interfering ribonucleic acid (RNA) market research report is one of a series of new reports from the business research company that provides small interfering ribonucleic acid (RNA) market statistics, including small interfering ribonucleic acid (RNA) industry global market size, regional shares, competitors with a small interfering ribonucleic acid (RNA) market share, detailed small interfering ribonucleic acid (RNA) market segments, market trends and opportunities, and any further data you may need to thrive in the small interfering ribonucleic acid (RNA) industry. This small interfering ribonucleic acid (RNA) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The small interfering ribonucleic acid (RNA) market size has grown exponentially in recent years. It will grow from $15.65 billion in 2024 to $18.86 billion in 2025 at a compound annual growth rate (CAGR) of 20.5%. The growth in the historic period can be attributed to rising government funding, increasing awareness of genetic disorders, growing clinical trials for small interfering ribonucleic acid (siRNA) therapies, expansion of biotechnology infrastructure, and rising adoption of targeted therapeutics. biotechnology infrastructure, and increasing adoption of targeted therapeutics.

The small interfering ribonucleic acid (RNA) market size is expected to see exponential growth in the next few years. It will grow to $39.26 billion in 2029 at a compound annual growth rate (CAGR) of 20.1%. The growth in the forecast period can be attributed to rising demand for personalized medicine, growing investment in small interfering ribonucleic acid (siRNA) research, increasing collaborations between pharma companies, and rising approvals of small interfering ribonucleic acid (siRNA) based drugs. Major trends in the forecast period include technological advancements in delivery methods, innovations in RNAi therapeutics, developments in lipid nanoparticle carriers, research and development in gene silencing, and advancements in targeted drug delivery systems.

The rising demand for personalized medicine is expected to drive the growth of the small interfering ribonucleic acid (RNA) market in the coming years. Personalized medicine is an approach that tailors treatments to individual patients based on their genetic, environmental, and lifestyle factors to optimize outcomes and improve care. Demand is increasing due to advancements in genomic technologies, which allow precise identification of genetic variations and enable customized treatments for individuals. Small interfering ribonucleic acid (siRNA) supports personalized medicine by enabling targeted gene silencing, making it suitable for treating specific genetic disorders and diseases. It minimizes off-target effects by selectively inhibiting disease-causing mRNA, enhancing therapeutic efficacy and patient outcomes. For example, in February 2024, according to the Personalized Medicine Coalition, a US based nonprofit organization, the U.S. Food and Drug Administration approved 26 new personalized medicines in 2023, a notable increase from 12 approvals in 2022. Therefore, the growing demand for personalized medicine is driving the expansion of the small interfering ribonucleic acid (RNA) market.

Major companies in the small interfering ribonucleic acid (siRNA) therapeutics market are pursuing regulatory approvals for novel mechanisms to treat rare genetic diseases, aiming to provide sustained effects and reduce dosing frequency for patients. Regulatory approvals are official clearances that permit a therapy to be safely tested, marketed, or used in patients. For instance, in March 2025, Alnylam Pharmaceuticals Inc., a US based biopharmaceutical company, received approval from the U.S. Food and Drug Administration for Qfitlia (fitusiran), the first siRNA-based therapy for adults and adolescents aged 12 years and older with hemophilia A or B, with or without inhibitors. The therapy is designed to lower antithrombin levels, enhancing thrombin generation to promote clot formation and reduce bleeding episodes. Qfitlia provides a subcutaneous, once-every-two-month dosing regimen, offering a novel, non-factor therapeutic option for hemophilia management.

In May 2025, AbbVie Inc., a US based biopharmaceutical company, partnered with ADARx Pharmaceuticals Inc. Through this partnership, AbbVie aims to combine ADARx's proprietary RNA technology with its scientific expertise to develop next-generation siRNA therapies, advancing treatment in neuroscience, immunology, and oncology. ADARx Pharmaceuticals Inc. is a biotechnology company developing siRNA-based therapies that target specific mRNA to treat diseases.

Major companies operating in the small interfering ribonucleic acid (rna) market are Novartis AG, Thermo Fisher Scientific Inc., GlaxoSmithKline plc, Sanofi S.A., Sarepta Therapeutics Inc., Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Wave Life Sciences Ltd., Silence Therapeutics plc, Arrowhead Pharmaceuticals Inc., Quark Pharmaceuticals Inc., Arbutus Biopharma Corporation, Evox Therapeutics Ltd., Phio Pharmaceuticals Inc., Genecon Biotechnologies Co., Ltd., Olix Pharmaceuticals, Inc., Benitec Biopharma Ltd., Bio-Path Holdings, Inc., Calando Pharmaceuticals, Inc., Sirnaomics, Ltd.

North America was the largest region in the small interfering ribonucleic acid (RNA) market in 2024. The regions covered in small interfering ribonucleic acid (RNA) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the small interfering ribonucleic acid (RNA) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The small interfering ribonucleic acid (RNA) market consists of revenues earned by entities by providing services such as gene silencing assays, delivery system development, molecular diagnostics, preclinical testing, and laboratory research support. The market value includes the value of related goods sold by the service provider or included within the service offering. The small interfering ribonucleic acid (RNA) market also includes sales of synthesis kits, lipid nanoparticles, delivery vectors, RNAi assay kits, transfection reagents, and RNA extraction kits. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Small Interfering Ribonucleic Acid (RNA) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on small interfering ribonucleic acid (rna) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for small interfering ribonucleic acid (rna) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The small interfering ribonucleic acid (rna) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Type: Liposome Systemic Therapy; Nanoparticle-Based Systemic Therapy
  • 2) By Indication: Cardiovascular Diseases; Respiratory Diseases; Oncology; Neurodegenerative Diseases; Infectious Diseases
  • 3) By End-User: Hospital; Research Institutions; Pharmaceutical And Biotechnology Companies; Academic Institutions
  • Subsegments:
  • 1) By Liposome Systemic Therapy: Cationic Liposome Delivery; Neutral Liposome Delivery; Pegylated Liposome Delivery; Targeted Liposome Delivery
  • 2) By Nanoparticle-Based Systemic Therapy: Lipid Nanoparticle Delivery; Polymer Nanoparticle Delivery; Gold Nanoparticle Delivery; Silica Nanoparticle Delivery
  • Companies Mentioned: Novartis AG; Thermo Fisher Scientific Inc.; GlaxoSmithKline plc; Sanofi S.A.; Sarepta Therapeutics Inc.; Alnylam Pharmaceuticals Inc.; Ionis Pharmaceuticals Inc.; Wave Life Sciences Ltd.; Silence Therapeutics plc; Arrowhead Pharmaceuticals Inc.; Quark Pharmaceuticals Inc.; Arbutus Biopharma Corporation; Evox Therapeutics Ltd.; Phio Pharmaceuticals Inc.; Genecon Biotechnologies Co., Ltd.; Olix Pharmaceuticals, Inc.; Benitec Biopharma Ltd.; Bio-Path Holdings, Inc.; Calando Pharmaceuticals, Inc.; Sirnaomics, Ltd.
  • Countries:

Table of Contents

1. Executive Summary

2. Small Interfering Ribonucleic Acid (RNA) Market Characteristics

3. Small Interfering Ribonucleic Acid (RNA) Market Trends And Strategies

4. Small Interfering Ribonucleic Acid (RNA) Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

  • 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Small Interfering Ribonucleic Acid (RNA) Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Small Interfering Ribonucleic Acid (RNA) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Small Interfering Ribonucleic Acid (RNA) Market Growth Rate Analysis
  • 5.4. Global Small Interfering Ribonucleic Acid (RNA) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Small Interfering Ribonucleic Acid (RNA) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Small Interfering Ribonucleic Acid (RNA) Total Addressable Market (TAM)

6. Small Interfering Ribonucleic Acid (RNA) Market Segmentation

  • 6.1. Global Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Liposome Systemic Therapy
  • Nanoparticle-Based Systemic Therapy
  • 6.2. Global Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Cardiovascular Diseases
  • Respiratory Diseases
  • Oncology
  • Neurodegenerative Diseases
  • Infectious Diseases
  • 6.3. Global Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospital
  • Research Institutions
  • Pharmaceutical And Biotechnology Companies
  • Academic Institutions
  • 6.4. Global Small Interfering Ribonucleic Acid (RNA) Market, Sub-Segmentation Of Liposome Systemic Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Cationic Liposome Delivery
  • Neutral Liposome Delivery
  • Pegylated Liposome Delivery
  • Targeted Liposome Delivery
  • 6.5. Global Small Interfering Ribonucleic Acid (RNA) Market, Sub-Segmentation Of Nanoparticle-Based Systemic Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Lipid Nanoparticle Delivery
  • Polymer Nanoparticle Delivery
  • Gold Nanoparticle Delivery
  • Silica Nanoparticle Delivery

7. Small Interfering Ribonucleic Acid (RNA) Market Regional And Country Analysis

  • 7.1. Global Small Interfering Ribonucleic Acid (RNA) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Small Interfering Ribonucleic Acid (RNA) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Small Interfering Ribonucleic Acid (RNA) Market

  • 8.1. Asia-Pacific Small Interfering Ribonucleic Acid (RNA) Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Small Interfering Ribonucleic Acid (RNA) Market

  • 9.1. China Small Interfering Ribonucleic Acid (RNA) Market Overview
  • 9.2. China Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Small Interfering Ribonucleic Acid (RNA) Market

  • 10.1. India Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Small Interfering Ribonucleic Acid (RNA) Market

  • 11.1. Japan Small Interfering Ribonucleic Acid (RNA) Market Overview
  • 11.2. Japan Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Small Interfering Ribonucleic Acid (RNA) Market

  • 12.1. Australia Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Small Interfering Ribonucleic Acid (RNA) Market

  • 13.1. Indonesia Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Small Interfering Ribonucleic Acid (RNA) Market

  • 14.1. South Korea Small Interfering Ribonucleic Acid (RNA) Market Overview
  • 14.2. South Korea Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Small Interfering Ribonucleic Acid (RNA) Market

  • 15.1. Western Europe Small Interfering Ribonucleic Acid (RNA) Market Overview
  • 15.2. Western Europe Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Small Interfering Ribonucleic Acid (RNA) Market

  • 16.1. UK Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Small Interfering Ribonucleic Acid (RNA) Market

  • 17.1. Germany Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Small Interfering Ribonucleic Acid (RNA) Market

  • 18.1. France Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Small Interfering Ribonucleic Acid (RNA) Market

  • 19.1. Italy Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Small Interfering Ribonucleic Acid (RNA) Market

  • 20.1. Spain Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Small Interfering Ribonucleic Acid (RNA) Market

  • 21.1. Eastern Europe Small Interfering Ribonucleic Acid (RNA) Market Overview
  • 21.2. Eastern Europe Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Small Interfering Ribonucleic Acid (RNA) Market

  • 22.1. Russia Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Small Interfering Ribonucleic Acid (RNA) Market

  • 23.1. North America Small Interfering Ribonucleic Acid (RNA) Market Overview
  • 23.2. North America Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Small Interfering Ribonucleic Acid (RNA) Market

  • 24.1. USA Small Interfering Ribonucleic Acid (RNA) Market Overview
  • 24.2. USA Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Small Interfering Ribonucleic Acid (RNA) Market

  • 25.1. Canada Small Interfering Ribonucleic Acid (RNA) Market Overview
  • 25.2. Canada Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Small Interfering Ribonucleic Acid (RNA) Market

  • 26.1. South America Small Interfering Ribonucleic Acid (RNA) Market Overview
  • 26.2. South America Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Small Interfering Ribonucleic Acid (RNA) Market

  • 27.1. Brazil Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Small Interfering Ribonucleic Acid (RNA) Market

  • 28.1. Middle East Small Interfering Ribonucleic Acid (RNA) Market Overview
  • 28.2. Middle East Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Small Interfering Ribonucleic Acid (RNA) Market

  • 29.1. Africa Small Interfering Ribonucleic Acid (RNA) Market Overview
  • 29.2. Africa Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Small Interfering Ribonucleic Acid (RNA) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Small Interfering Ribonucleic Acid (RNA) Market Competitive Landscape And Company Profiles

  • 30.1. Small Interfering Ribonucleic Acid (RNA) Market Competitive Landscape
  • 30.2. Small Interfering Ribonucleic Acid (RNA) Market Company Profiles
    • 30.2.1. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Sarepta Therapeutics Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Small Interfering Ribonucleic Acid (RNA) Market Other Major And Innovative Companies

  • 31.1. Alnylam Pharmaceuticals Inc.
  • 31.2. Ionis Pharmaceuticals Inc.
  • 31.3. Wave Life Sciences Ltd.
  • 31.4. Silence Therapeutics plc
  • 31.5. Arrowhead Pharmaceuticals Inc.
  • 31.6. Quark Pharmaceuticals Inc.
  • 31.7. Arbutus Biopharma Corporation
  • 31.8. Evox Therapeutics Ltd.
  • 31.9. Phio Pharmaceuticals Inc.
  • 31.10. Genecon Biotechnologies Co., Ltd.
  • 31.11. Olix Pharmaceuticals, Inc.
  • 31.12. Benitec Biopharma Ltd.
  • 31.13. Bio-Path Holdings, Inc.
  • 31.14. Calando Pharmaceuticals, Inc.
  • 31.15. Sirnaomics, Ltd.

32. Global Small Interfering Ribonucleic Acid (RNA) Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Small Interfering Ribonucleic Acid (RNA) Market

34. Recent Developments In The Small Interfering Ribonucleic Acid (RNA) Market

35. Small Interfering Ribonucleic Acid (RNA) Market High Potential Countries, Segments and Strategies

  • 35.1 Small Interfering Ribonucleic Acid (RNA) Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Small Interfering Ribonucleic Acid (RNA) Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Small Interfering Ribonucleic Acid (RNA) Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer